Cargando…
Silibinin Therapy Improves Cholangiocarcinoma Outcomes by Regulating ERK/Mitochondrial Pathway
Background: Silibinin is widely utilized drug in various cancer treatments, though its application in cholangiocarcinoma has not yet been explored. For the first time, we evaluated the anticancer potential and underlying molecular mechanism of silibinin in treatment of cholangiocarcinoma treatment....
Autores principales: | Bai, Yang, Chen, Jiaqi, Hu, Weijian, Wang, Lei, Wu, Yulian, Yu, Shi’an |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983842/ https://www.ncbi.nlm.nih.gov/pubmed/35401195 http://dx.doi.org/10.3389/fphar.2022.847905 |
Ejemplares similares
-
Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway
por: Hou, Xiaoying, et al.
Publicado: (2018) -
Silibinin Regulates Lipid Metabolism and Differentiation in Functional Human Adipocytes
por: Barbagallo, Ignazio, et al.
Publicado: (2016) -
MLN2238 exerts its anti-tumor effects via regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma
por: Xu, Hao, et al.
Publicado: (2022) -
Inhibition of TMEM16A by Natural Product Silibinin: Potential Lead Compounds for Treatment of Lung Adenocarcinoma
por: Guo, Shuai, et al.
Publicado: (2021) -
Silibinin Induces G2/M Cell Cycle Arrest by Activating Drp1-Dependent Mitochondrial Fission in Cervical Cancer
por: You, Yanting, et al.
Publicado: (2020)